Patient
SITE003-0112
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE003 (CAN) (Dr. Okafor)
consented 2026-01-18
Adverse events
8
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 108); relationship: not assessed
Grade 2 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-11-03 (study day 105); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 101); relationship: NOT RELATED
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 90); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-10-10 (study day 81); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 60); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-09-01 (study day 42); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 22); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.